Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190028/S026

cobas HPV

Roche Molecular Systems, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP190028/S026

What did the FDA decide?

FDA posted a 30-day notice for PMA supplement P190028/S026 from Roche Molecular Systems, Inc. The decision record, dated 2026-10-27, lists the supplement reason as a process change involving manufacturer, sterilizer, packager, or supplier, and the statement says the purpose is to change the manufacturing process for oligonucleotides. The device is identified as a kit for DNA detection of human papillomavirus under product code MAQ.

The posted record does not include the attached FDA summary or other documents, so the specific oligonucleotide change, affected manufacturing site, and any labeling or performance details are absent. This supplement is not a new approval of the whole system and does not by itself establish safety or clinical effectiveness. The relationship to the original PMA is limited to the identifier P190028.

FDA approval order statement

to change the manufacturing process for oligonucleotides
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P190028/S026
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

For the original device and its historical approval scope, see PMA P190028. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190028 · Original PMA

    cobas HPV for use on the cobas 6800/8800 Systems

  2. P190028/S026 received

    Application receipt date recorded by FDA.

  3. P190028/S026 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P190028. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190028

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalApr 3, 2020FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Abbott Molecular, Inc.PMA approvalNov 1, 2023FDA
Roche Molecular Systems, Inc.PMA approvalApr 19, 2011FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records